Sector

Biotech & Longevity

Gene editing, mRNA platforms, precision medicine, and the science of extending human lifespan.

🧬 Biotech is binary at the stock level — drug approval or failure. Platform plays offer more diversified exposure to the underlying science.

Why This Sector Matters

CRISPR gene editing, mRNA vaccines, and AI-driven drug discovery have compressed timelines that once took decades. The convergence of biology with computation is creating an entirely new investment category — one that’s no longer science fiction. Longevity research has moved from fringe to serious capital deployment: Bezos, Altman, and dozens of sovereign wealth funds are funding lifespan extension science.

Key Sub-Themes

Gene Editing — CRISPR-Cas9 editing of somatic and germline cells. CRSP, EDIT, and BEAM each use different editing mechanisms with different target diseases and IP positions. In-vivo editing (directly in the body) is the frontier.

mRNA Platforms — Moderna and BioNTech built the world’s most proven mRNA delivery infrastructure. Their pipelines now include cancer vaccines, rare disease, and respiratory. The platform is the asset.

AI Drug Discovery — Recursion (RXRX) uses imaging + AI to screen millions of compound-disease interactions. Insilico, Isomorphic (DeepMind spinout) are non-listed. Biotech + AI = 10× pipeline speed.

Longevity Science — Senolytics, rapamycin derivatives, GLP-1 extensions, epigenetic reprogramming. Calico (Alphabet), Altos Labs, and Unity Biotechnology (UNTY) are the listed/semi-listed plays.

Genomics Infrastructure — Illumina sequencing technology underpins all genomics research. Every gene editing company is an Illumina customer.

Listed Stocks

Ticker Company Focus Stage
CRSP CRISPR Therapeutics Gene editing Commercial (sickle cell approved)
EDIT Editas Medicine CRISPR / eye disease Clinical
MRNA Moderna mRNA platform Commercial
BNTX BioNTech mRNA + cancer vaccines Commercial
ILMN Illumina Genomic sequencing Commercial
BEAM Beam Therapeutics Base editing Clinical
RXRX Recursion Pharma AI drug discovery Revenue
ISRG Intuitive Surgical Surgical robotics Commercial

Filter Biotech stocks →

Civilization Dependency Chain

Human Genome Project → Next-Gen Sequencing → CRISPR Editing → In-Vivo Repair
→ Disease Elimination → Longevity Protocols → Healthy Century Lifespans
→ Epigenetic Reprogramming → Biological Age Reversal

Sequencing cost must drop to ~$100 (it’s at ~$200 now). When it does, personalised medicine becomes routine and the market expands by orders of magnitude.

  • Now–2028: CRISPR therapeutics FDA approvals, mRNA cancer vaccines Phase 3, AI drug discovery IPOs
  • 2028–2030: First longevity drugs in clinical trials, AI-designed proteins commercial
  • 2030+: Epigenetic age reversal, personalised gene therapy, synthetic biology manufacturing

Deep Dive Articles — Coming Soon

CRISPR platform comparisons, mRNA pipeline analysis, and the longevity investment thesis.